Lactobacillus Plantarum as Therapy for NK-T Cell Deficiency

National Center for Research Resources (NCRR)

Status: Completed

Conditions: Diabetes Mellitus

Treatments: Drug: Oral lactobacillus administration

Study type: Interventional

Funder types: NIH

Identifiers

NCT00011141

NCRR-M01RR06020-0165

Details and patient eligibility

About

The etiology of immune-mediated diabetes mellitus (IMD) remains unclear. However, previous studies indicate that autoimmunity may be a result of dysfunction of natural killer T cells (NK-T cells). Newly diagnoses patients with IMD have been shown in our laboratory to have significantly lower NK-T cells than normal controls. Other studies have shown that oral administration of lactobacillus can boost NK-T cell activity in children with HIV without side effects. Our objective is to evaluate the effect of lactobacillus administration on NK-T cell activity in patients with IMD

Sex: All

Ages: 1 to 95 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Recently diagnosed (within the last 6 months) patients with immune-mediated (type 1) diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Double Blind